- ongoing, recruitingHuman Pharmacology (Phase I)- Other
Phase 1 study of NG-641 plus nivolumab (or standard of care PD-1) in metastatic or advanced epithelial tumours (NEBULA)
This study is looking into a new treatment called NG-641, used with an existing cancer medicine (nivolumab or similar), for people with advanced or spreading cancer. It's a very early-stage trial, focusing on safety and how the new treatment works in the body.
Belgium · Spain - ongoing, recruitingPhase I and Phase II (Integrated)- Other
Phase 1 study of NG-350A plus pembrolizumab in metastatic or advanced epithelial tumours (FORTIFY)
This study, called FORTIFY, is testing a new treatment called NG-350A along with an existing cancer drug, pembrolizumab. It's for adults with advanced or spreading cancers that start in the lining of organs, like skin or glands. This is an early-stage study to see if the treatment is safe.
Belgium · Spain